BACKGROUND: The objective of this study was to determine spectrum and prevalence of germline mutations in TP53 gene among Polish women with early-onset breast cancer (BC), which has not been determined until now. METHODS: A cohort of 100 females with BC diagnosed ≤ 30 years of age and with a positive family history of cancer was used as a discovery cohort. 1880 women with BC ≤ 45 years old and a control group of 2000 healthy women were genotyped as a replication phase of this study. RESULTS: Four heterozygous pathogenic missense mutations were detected in a group of 100 patients with early-onset breast cancer. On the basis of software prediction and available literature data, all these variants were defined as pathogenic. None of these TP53 variants were detected among 1880 breast cancer patients and 2000 healthy controls. No large mutations were found among early-onset cases using MLPA reaction. CONCLUSION: Germline pathogenic TP53 variants were found in 4% early-onset Polish BC patients. No founder mutations were identified in Polish population. To improve the treatment and surveillance screening, the search for germline TP53 pathogenic variants is recommended for all female BC cases diagnosed ≤ 30 years old.
BACKGROUND: The objective of this study was to determine spectrum and prevalence of germline mutations in TP53 gene among Polish women with early-onset breast cancer (BC), which has not been determined until now. METHODS: A cohort of 100 females with BC diagnosed ≤ 30 years of age and with a positive family history of cancer was used as a discovery cohort. 1880 women with BC ≤ 45 years old and a control group of 2000 healthy women were genotyped as a replication phase of this study. RESULTS: Four heterozygous pathogenic missense mutations were detected in a group of 100 patients with early-onset breast cancer. On the basis of software prediction and available literature data, all these variants were defined as pathogenic. None of these TP53 variants were detected among 1880 breast cancerpatients and 2000 healthy controls. No large mutations were found among early-onset cases using MLPA reaction. CONCLUSION: Germline pathogenic TP53 variants were found in 4% early-onset Polish BC patients. No founder mutations were identified in Polish population. To improve the treatment and surveillance screening, the search for germline TP53 pathogenic variants is recommended for all female BC cases diagnosed ≤ 30 years old.
Authors: D M Eccles; N Li; R Handwerker; T Maishman; E R Copson; L T Durcan; S M Gerty; L Jones; D G Evans; L Haywood; I Campbell Journal: Ann Oncol Date: 2015-12-17 Impact factor: 32.976
Authors: Phuong L Mai; David Malkin; Judy E Garber; Joshua D Schiffman; Jeffrey N Weitzel; Louise C Strong; Oliver Wyss; Luana Locke; Von Means; Maria Isabel Achatz; Pierre Hainaut; Thierry Frebourg; D Gareth Evans; Eveline Bleiker; Andrea Patenaude; Katherine Schneider; Benjamin Wilfond; June A Peters; Paul M Hwang; James Ford; Uri Tabori; Simona Ognjanovic; Phillip A Dennis; Ingrid M Wentzensen; Mark H Greene; Joseph F Fraumeni; Sharon A Savage Journal: Cancer Genet Date: 2012-08-29
Authors: J J Bakhuizen; F B Hogervorst; M E Velthuizen; M W Ruijs; K van Engelen; T A van Os; J J Gille; M Collée; A M van den Ouweland; C J van Asperen; C M Kets; A R Mensenkamp; E M Leter; M J Blok; M M de Jong; M G Ausems Journal: Fam Cancer Date: 2019-04 Impact factor: 2.375
Authors: Tom Walsh; Silvia Casadei; Kathryn Hale Coats; Elizabeth Swisher; Sunday M Stray; Jake Higgins; Kevin C Roach; Jessica Mandell; Ming K Lee; Sona Ciernikova; Lenka Foretova; Pavel Soucek; Mary-Claire King Journal: JAMA Date: 2006-03-22 Impact factor: 56.272
Authors: Christian P Kratz; Maria Isabel Achatz; Laurence Brugières; Thierry Frebourg; Judy E Garber; Mary-Louise C Greer; Jordan R Hansford; Katherine A Janeway; Wendy K Kohlmann; Rose McGee; Charles G Mullighan; Kenan Onel; Kristian W Pajtler; Stefan M Pfister; Sharon A Savage; Joshua D Schiffman; Katherine A Schneider; Louise C Strong; D Gareth R Evans; Jonathan D Wasserman; Anita Villani; David Malkin Journal: Clin Cancer Res Date: 2017-06-01 Impact factor: 12.531
Authors: Jeanna M McCuaig; Susan R Armel; Ana Novokmet; Ophira M Ginsburg; Rochelle Demsky; Steven A Narod; David Malkin Journal: Fam Cancer Date: 2012-12 Impact factor: 2.375
Authors: Suzanna L Arcand; Mohammed R Akbari; Anne-Marie Mes-Masson; Diane Provencher; William D Foulkes; Steven A Narod; Patricia N Tonin Journal: BMC Med Genet Date: 2015-04-12 Impact factor: 2.103